Current state of research about Chinese Herbal Medicines (CHM) for the treatment of Coronavirus Disease 2019 (COVID-19): A scoping review

López-Alcalde, Jesús ; Yan, Yuqian ; Witt, Claudia M ; Barth, Jürgen

Abstract: Background: There is currently no effective treatment against coronavirus disease 2019 (COVID-19). The optimal selection of interventions targeting the virus is unknown. Therefore, evidence from randomized controlled trials (RCTs) to support specific treatment against COVID-19 is urgently needed. The use of Chinese herbal medicines (CHMs) might have a role in the treatment and symptomatic management of patients with COVID-19. It was aimed at providing an overview of the available evidence and ongoing trials concerning the effects of CHMs for the treatment of COVID-19. Methods: This is a narrative review of relevant studies. Searches were conducted to identify documents published till April 22, 2020. Electronic databases, evidence-based collections, websites of relevant organizations, and trial registries were consulted. Results: A total of 25 guidelines on the treatment of patients with COVID-19 were identified. Four guidelines provided recommendations on the use of CHMs; these guidelines were developed in China and South Korea and were based on the consensus of experts exclusively. The remaining 21 guidelines provided no guidance on CHMs. No finished RCTs of CHMs for the treatment of patients with COVID-19 was found. According to the evidence evaluated in this review, a Cochrane review of CHMs for severe acute respiratory syndrome and five uncontrolled observational studies of the effects of CHMs in patients with COVID-19, the effects of CHMs for COVID-19 are unknown. A total of 52 ongoing clinical trials of CHM interventions for the treatment of COVID-19 were found. These trials will be carried out mostly in China (n = 51). Forty (77%) of the ongoing trials will be randomized, whereas 12 (23%) have an unclear sequence generation procedure. Forty-seven trials (90%) will have a sample size <400 participants. Conclusions: To the authors’ knowledge, only the Chinese and the South Korean guidelines recommend CHMs as a treatment option for patients with COVID-19. These guidelines base their recommendations on the consensus of experts. Clinical guidelines or health authorities from other countries do not provide advice on CHMs. Due to the absence of RCT, there is currently no reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. A high number of clinical trials of different herbal products are being currently conducted in China.

DOI: https://doi.org/10.1089/acm.2020.0189
López-Alcalde, Jesús; Yan, Yuqian; Witt, Claudia M; Barth, Jürgen (2020). Current state of research about Chinese Herbal Medicines (CHM) for the treatment of Coronavirus Disease 2019 (COVID-19): A scoping review. Journal of Alternative and Complementary Medicine, 26(7):557-570.
DOI: https://doi.org/10.1089/acm.2020.0189
Current State of Research About Chinese Herbal Medicines (CHM) for the Treatment of Coronavirus Disease 2019 (COVID-19):
A Scoping Review

Jesús López-Alcalde, MD,1–4 Yuqian Yan, MD,1 Claudia M. Witt, MD,1,5,6 and Jürgen Barth, PhD1

Abstract

Background: There is currently no effective treatment against coronavirus disease 2019 (COVID-19). The optimal selection of interventions targeting the virus is unknown. Therefore, evidence from randomized controlled trials (RCTs) to support specific treatment against COVID-19 is urgently needed. The use of Chinese herbal medicines (CHMs) might have a role in the treatment and symptomatic management of patients with COVID-19. It was aimed at providing an overview of the available evidence and ongoing trials concerning the effects of CHMs for the treatment of COVID-19.

Methods: This is a narrative review of relevant studies. Searches were conducted to identify documents published till April 22, 2020. Electronic databases, evidence-based collections, websites of relevant organizations, and trial registries were consulted.

Results: A total of 25 guidelines on the treatment of patients with COVID-19 were identified. Four guidelines provided recommendations on the use of CHMs; these guidelines were developed in China and South Korea and were based on the consensus of experts exclusively. The remaining 21 guidelines provided no guidance on CHMs. No finished RCTs of CHMs for the treatment of patients with COVID-19 was found. According to the evidence evaluated in this review, a Cochrane review of CHMs for severe acute respiratory syndrome and five uncontrolled observational studies of the effects of CHMs in patients with COVID-19, the effects of CHMs for COVID-19 are unknown. A total of 52 ongoing clinical trials of CHM interventions for the treatment of COVID-19 were found. These trials will be carried out mostly in China (n=51). Forty (77%) of the ongoing trials will be randomized, whereas 12 (23%) have an unclear sequence generation procedure. Forty-seven trials (90%) will have a sample size <400 participants.

Conclusions: To the authors’ knowledge, only the Chinese and the South Korean guidelines recommend CHMs as a treatment option for patients with COVID-19. These guidelines base their recommendations on the consensus of experts. Clinical guidelines or health authorities from other countries do not provide advice on CHMs. Due to the absence of RCT, there is currently no reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. A high number of clinical trials of different herbal products are being currently conducted in China.

Keywords: COVID-19, complementary, alternative and integrative medicine, Traditional Chinese Medicine, Chinese herbal medicine, narrative review

1Institute for Complementary and Integrative Medicine, University Hospital Zurich and University Zurich, Zurich, Switzerland.
2Faculty of Health Sciences, Universidad Francisco de Vitoria (UFV), Madrid, Spain.
3Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Unidad de bioestadística clínica, Hospital Universitario Ramón y Cajal, Madrid, Spain.
4The Biomedical Research Center Network for Epidemiology and Public Health (CIBERESP), Madrid, Spain.
5Institute for Social Medicine, Epidemiology and Health Economics, Charité–Universitätsmedizin Berlin, Berlin, Germany.
6Center for Integrative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Introduction

Coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 has rapidly spread globally since an outbreak first reported in Wuhan in December 2019. As declared by the World Health Organization (WHO) on March 11, COVID-19 is a "public health emergency of international concern," and the pandemic is overwhelming health care facilities worldwide.

There is currently no effective treatment against COVID-19. The optimal selection of antiviral agents and interventions targeting the virus is unknown. Therefore, high-quality evidence from randomized controlled trials (RCTs) to support decisions concerning the treatment of COVID-19 is urgently needed.

Traditional Chinese Medicine (TCM) is an essential part of the health care system in China.1,2 The WHO recognizes this situation and supports the Member States of the Western Pacific Region to integrate traditional medicine into their national health systems.3 In this line, the WHO International Classification of Diseases (ICD 11) has introduced a new chapter on traditional medicine.4 TCM is also used in Western countries and is recognized as a complementary or alternative medicine.5–7

Chinese herbal medicines (CHMs) are an essential part of TCM.7 CHMs include single herbs, Chinese proprietary medicines, and mixtures of different herbs,8 which might be used alone or in combination with Western medicines. CHMs might have a role in the treatment and symptomatic management of patients with COVID-19.9,10 Herbal plants are routinely used for treating viral respiratory infections in China and might have compounds with capacity against 2019-nCoV.11 CHMs are considered to have a generalized antiviral effect based on the direct inhibition of viruses, and the control of the associated inflammatory response. Previous in vitro studies of Chinese medicinal herbs have suggested their antiviral activity. For instance, Weng et al. demonstrated the activity of Sambucus Formosana Nakai ethanol extract against human coronavirus NL63.12

The state administration of TCM of the People’s Republic of China, in collaboration with the WHO, initiated clinical research projects on integrated TCM and conventional medicine for the management of SARS.13 A total of 21 projects covering prevention and treatment were already started, but firm conclusions on intervention efficacy could not be drawn yet. Experts recommended WHO continue to support the research of TCM in treating SARS and other diseases.13

The Institute for Complementary and Integrative Medicine14 (Zurich University Hospital) has prepared this report to summarize the evidence concerning CHMs for the treatment of COVID-19. This review has three specific objectives. First, to describe the recommendations on the use of CHMs for the treatment of COVID-19 in clinical guidelines and documents of relevant organizations. Second, to summarize the evidence on CHMs in patients with COVID-19. Third, to provide an overview of the ongoing RCTs of CHMs in patients with COVID-19.

Materials and Methods

This study is a scoping review and did not require written consent or institutional ethical review because it is based on published work exclusively.

Inclusion and exclusion criteria

Type of study designs. The focus of this review was to identify rigorous secondary research and RCTs on this review topic. Thus, we looked for evidence-based clinical guidelines, health technology assessments, systematic reviews, and RCTs. If there was no secondary research or RCTs available, nonrandomized trials were looked for, that is, quasi-randomized controlled trials (quasi-RCTs) and nonrandomized clinical trials. Only if previous designs were not found, observational studies, narrative reviews, and opinion of experts were included. Since it was expected that the evidence base would be scarce or absent, systematic reviews on the effects of CHMs in patients with SARS were also included.

Types of participants. Patients with COVID-19 (the diagnosis as provided by the study authors was accepted). A specific set of diagnostic criteria was not required as these have changed since the beginning of the outbreak.

Types of interventions. Studies evaluating the use of CHMs (combined or not with conventional medicines) for the treatment of patients with COVID-19 were included. To classify an intervention as CHMs, the operational definition provided by the Cochrane review on Chinese herbs combined with Western medicine for SARS was followed.8,15 Consequently, Chinese herbs were defined as “either raw or refined products derived from plants or parts of plants (e.g., leaves, stems, buds, flowers, roots, or tubers) used for treating diseases.”8,15 Therefore, this review also covered herbal products used in other countries besides China under the Traditional Eastern Asian Medicine, such as South Korea and Japan. This includes decoction of raw herbs prepared in medical facilities, or concentrated herbal extracts provided according to good manufacture practices by pharmaceutical companies.

This review excluded other interventions defined in Western countries as complementary, alternative, or integrative therapies, such as the use of vitamins or other food supplements, mind–body exercises (e.g., t’ai chi, yoga), psychotherapy, or acupuncture.

We included studies with any comparator and co-interventions. To include a study, the co-interventions should be similar in both study groups to allow determining the effects of CHMs.

Types of outcome measures. It was planned to assess the following outcomes measured at the end of treatment or the end of follow-up: all-cause mortality; COVID-19–related mortality; days to loss of fever; symptom scores (symptoms included fever, fatigue, cough, poor appetite, perspiration, constipation, and diarrhea); duration of symptoms; duration of absorption of pulmonary infiltration; absorption of pulmonary infiltration (assessed with chest X-ray); average daily dose of corticosteroid; dosage of corticosteroid at the end of treatment; duration of corticosteroid treatment; quality of life; number of days in the hospital; and adverse effects. These outcomes were similar to those measured in a Cochrane review of Chinese herbs combined with Western medicine for SARS.8
Search methods for identification of studies

Literature searches were conducted looking for documents published till April 22, 2020, with no language of publication restriction. The following sources were consulted: (a) electronic databases (Tripdatabase; MEDBOX Rapid Response Toolbox; Epistemonikos; The Cochrane Database of Systematic Reviews [CDSR], and The Cochrane Central Register of Controlled Trials [CENTRAL]); (b) evidence-based collections; and (c) websites of relevant organizations. Experts in China were also contacted asking for related studies or guidelines. To identify ongoing RCTs evaluating interventions for the treatment of COVID-19, the Cochrane COVID-19 Study Register was consulted. Appendix A1 details the search strategies used. The results of the searches were managed with the software Endnote X7.17

Analysis methods

A narrative description of the evidence found was provided and any meta-analysis was not foreseen to be performed.

Results

Appendix A2 lists all the documents consulted for this report.

Description of the studies

The electronic searches until April 23, 2020, identified a total of 641 records after removal of duplicates. The review finally included 25 guidelines, 1 systematic review, no RCT, and 52 ongoing trials (40 RCTs and 12 trials with unclear randomization). Figure 1 presents a flow diagram describing the results of the searches and the selection process.

Objective 1: To describe the recommendations on the use of CHMs for the treatment of COVID-19 in clinical guidelines and documents of relevant organizations

We identified a total of 25 guidelines providing recommendations on the treatment of patients with COVID-19 (Appendix A2). The guidelines were published in the following countries: United States (n = 5),18–22 United Kingdom (n = 4),23–26 Canada (n = 3),27–29 China (n = 3, reported in 4 publications),30–33 Australia (n = 2),34,35 Germany (n = 1),36 South Korea (n = 2),37,38 and Malaysia (n = 1).39 International organizations developed the remaining guidelines (n = 4), that is, the WHO,40,41 the European Centre for Disease Prevention and Control (ECDC),42 and the Surviving Sepsis Campaign.43 Sixty percent of the assessed guidelines were developed in Western countries (n = 15), whereas 24% (n = 6) in Asia.

The three Chinese guidelines30–32 and the Korean Traditional Medicine guidelines38 were the only ones providing recommendations on CHMs for the treatment of COVID-19. The Surviving Sepsis Campaign guidelines43 did not provide any recommendation on CHMs, but they stated that several TCMs are undergoing testing. The remaining 20 guidelines (80%)18–29,33–37,39–42 provided no information on CHMs. Two additional guidelines44,45 were not included in our analysis as, although covering Traditional Chinese Medicine, the focus was on acupuncture.

FIG. 1. Flow chart. CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central Register of Controlled Trials; CHM, Chinese herbal medicine; RCT, randomized controlled trial; SRs, systematic reviews; TCM, Traditional Chinese Medicine.
The three Chinese guidelines\textsuperscript{30–32} and the Korean Traditional Medicine guidelines\textsuperscript{38} recommend CHMs as a treatment option for COVID-19. These guidelines are exclusively based on the consensus of experts, and the data to support the recommendations are not detailed. Following we provide a more detailed description of these guidelines.

1. National Health Commission (NHC), National Administration of Traditional Chinese Medicine, sixth edition\textsuperscript{32}

We consulted two documents related to this guideline: the full guideline,\textsuperscript{32} which contained the sixth version of the diagnosis and treatment plan for COVID-19, and a report with the seventh version of this chapter.\textsuperscript{31} The guideline claims that “COVID-19 can also be treated with Traditional Chinese Medicine” and describes in detail (including formulas and compounds) an exhaustive list of CHM options according to the clinical situation of the patient, covering from patients with “fatigue with gastrointestinal upset” to “critical patients.” For example, the guideline recommends administering Xue Bi Jing injection 100 mL/day, twice a day for the treatment of severe and critical cases. For patients with “fatigue with gastrointestinal upset,” Huoxiang Zhengqi (capsule/pill/oral liquid) is recommended. More examples of suggested CHM interventions are Qingfei Paidu decoction (QPD), Gancao Ganjiang decoction, Shegan Mahuang decoction, or Qingfei Touxi Fuqeng decoction (see more details in Ren et al.\textsuperscript{46} and the guidelines).\textsuperscript{32}

The authors state that “the guidelines were written based on the study, analysis and summary of the treatment of previous COVID-19 cases.” However, it seems that the recommendations are based on the experts’ experience, and no empirical data are provided to support these recommendations. It is also unclear how the guideline team managed their potential conflicts of interest, it seems that there was not a rigorous search of the literature, and there was no assessment of the quality of evidence.

2. Jin et al.\textsuperscript{30}

According to this article, these guidelines were developed according to the GRADE approach and the WHO guideline development manuals. However, the recommendations for the treatment of COVID-19 with CHMs are based on the guideline already described.\textsuperscript{32} Thus, the same conclusions on the limitations apply to these recommendations.

3. The First Affiliated Hospital, Zhejiang University School of Medicine\textsuperscript{33}

This guideline synthesizes the clinical experience of The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), in the treatment of COVID-19. The guide also has a section dedicated to CHMs. However, it has the same weaknesses of the previous two guidelines.

4. Association of Korean Medicine, Korean Association of Traditional Pulmonary Medicine\textsuperscript{38}

These guidelines recommend the use of CHMs for the treatment of COVID-19 and they are also based on the consensus of experts exclusively. The description of the methods of the guidelines is incomplete, so it could not be known whether there was a rigorous search strategy, the evidence that was considered, or whether there was any attempt to assess the certainty of the evidence.

Objective 2: To summarize the evidence on CHMs in patients with COVID-19

Systematic reviews (\textit{n}=1, indirect evidence). No systematic review of the effects of CHMs on the treatment of patients with COVID-19 was found. One Cochrane review published in 2012 was identified that evaluated the effects of Chinese herbs combined with conventional medicine for SARS.\textsuperscript{8} The review included 12 RCTs and 1 quasi-RCT. The review concluded that Chinese herbs plus conventional medicine did not reduce mortality in patients with SARS, as compared with conventional medicine alone. Besides, the review suggested that the addition of the Chinese herbs may have a beneficial impact on the following outcomes: symptoms, absorption of pulmonary infiltration, the average daily dose of corticosteroids, the dosage of corticosteroids, days of corticosteroid treatment, quality of life, and length of stay in hospital.\textsuperscript{45–56} It was considered that the potential benefits identified in this Cochrane review cannot be directly transferred to patients with COVID-19 because the results obtained from patients with SARS may not apply to patients with COVID-19. Besides, as highlighted in the Cochrane review, the quality of the evidence was low.

RCTs (\textit{n}=0). There is no current evidence from RCTs to recommend any specific anti-nCoV treatment for patients with suspected or confirmed COVID-19.\textsuperscript{30} Thus, the same conclusion applies to CHMs.

Observational studies (\textit{n}=5). Hereunder, five observational studies describing the effects of different preparations of CHMs in patients with COVID-19 are presented. All these studies are descriptive (without a comparator) with small samples. Three studies are case reports (less than five patients in total),\textsuperscript{46,57,58} and one study is a series of 214 cases.\textsuperscript{59} The remaining study did not report the sample size.\textsuperscript{59}

All these studies share the common pitfalls inherent to uncontrolled designs, which do not allow determining the effects of an intervention; they can only suggest that there may be an effect. In addition to that, there was a poor report of the CHM compounds and the conventional treatment received.

1. Ren et al.\textsuperscript{46,60}

According to this one-case report, described in two articles,\textsuperscript{46,60} an early intervention with CHMs based on a plant-based mixture called QPD prevented the severe and critical disease in one patient with suspected COVID-19. This case report raises serious concerns mainly because it describes the success of just one patient and because the patient was not confirmed as suffering from COVID-19.\textsuperscript{61,62}

2. Yang et al.\textsuperscript{9}

According to this report, the State Administration of Traditional Chinese Medicine has recently recommended combining CHMs and conventional medicine for the treatment of COVID-19 pneumonia. As an example, QPD has been devised to be used in viral infections. According to Yang et al., in the 214 cases who received this treatment, the symptoms disappeared quickly, and there was a rapid disease recovery.

3. Wang et al.\textsuperscript{58}

This report described the care provided to four patients with mild-to-severe COVID-19. The patients received antiviral treatment (including lopinavir/ritonavir and arbidol), Shufeng Jiedu capsule, that is, a CHM herbal formula, and other necessary supportive care. The authors stated that Shufeng Jiedu capsule may alleviate acute lung injury in patients with COVID-19 and warrants further investigations.\textsuperscript{58}
4. Kaijin Xu et al.
This report describes the experience of treating patients with COVID-19 at the main hospital in Zhejiang (the number of patients treated is not reported). The authors state that they “[…] also integrated Chinese medicine in treatment to promote disease rehabilitation through classification methods of traditional Chinese medicine.” However, only the abstract could be accessed, which describes the intervention vaguely and does not provide any outcome measure to prove treatment effects.

5. Ni et al.
This report describes the first family case of COVID-19 confirmed in Wuhan. The three family members (parents and daughter) responded poorly to routine conventional treatments, so they also received Shuang Huang Lian (SHL) oral liquid, a Chinese Traditional patent Medicine. SHL contains extracts of three Chinese herbs, namely, honeysuckle, Forsythia, and Scutellaria baicalensis, and is used to treat sore throat, cold, and cough with fever. The report highlights that “the three cases […] achieved rapid recovery” and suggests that SHL treatment might be effective. Thus, the authors have started a clinical trial (ChiCTR2000029605) to assess the effects of SHL for the treatment of COVID-19. This multicenter nonblinded RCT seems to have started in February 2020.

Other studies (n = 3). To identify treatment options as soon as possible is critical to alleviating the impact of the COVID-19 outbreak. The WHO has published a list of candidate therapeutics, which does not include any CHM intervention. However, CHMs for the treatment of COVID-19 are still considered in China as an area that requires further clinical research. Zhang et al.11 proposed a system to screen CHM compounds that may be candidates against COVID-19. This approach has identified 13 natural compounds that exist in Chinese herbs with potential anti-SARS-CoV-2 activity. In total, 125 Chinese herbs contain 2 or more of these 13 compounds.

Objective 3: To provide an overview of the ongoing RCT of CHMs in patients with COVID-19

This search in the Cochrane COVID-19 Study Register threw a total of 521 ongoing trials on interventions to treat COVID-19 with a randomized or unclear assignment. After screening all these records, 52 ongoing trials were identified on the effects of CHMs for the treatment of COVID-19 (Table 1). These CHM trials represent 5.6% of the 921 trials of the Cochrane COVID-19 Study Register (consulted on April 23, 2020). In total, 46 out of the 52 trials (88%) were registered on the Chinese Clinical Trial Registry (ChiCTR), whereas only 6 (12%) in ClinicalTrials.gov. All the trials but one (NCT04322344; Italy) will be conducted in China.

Forty (77%) of the ongoing studies on CHMs have been planned to assign the participants to the study arms after a random sequence. The remaining 12 trials (23%) did not report whether they were randomized or not, so we assumed they were not. The planned sample sizes of the trials ranged from 20 to 550 participants (median 120 participants). Only five trials (10%) planned to obtain a sample of at least 400 participants. The trials will evaluate the effects of different herbal products administered orally (n = 40, 77%) or by injection (n = 12, 23%). In 11 (27.5%) of the 40 trials evaluating oral CHMs, the administration form (capsule, granules, tablets, liquid, etc.) was not reported. Table 1 lists all the CHM products that were evaluated. Besides, other nine studies assessing the effects of TCM in patients with COVID-19 were found, but could not conclude whether they focused on CHMs due to poor reporting of the interventions.

Discussion
Summary of main results
A total of 25 guidelines were identified on the treatment of patients with COVID-19. Only four guidelines, all developed in China and South Korea, included recommendations on the use of CHMs. These recommendations on herbal medicines were based on the consensus of experts exclusively.

This review did not find reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. No finished RCT was identified. In contrast, indirect evidence provided in a Cochrane review published in 2012 was found on the effects of Chinese herbs combined with conventional medicine in patients with SARS. This Cochrane review concluded that Chinese herbs did not reduce mortality, but that they may have a beneficial effect in several clinical outcomes, such as symptoms, or the absorption of pulmonary infiltration. However, the review authors rated the quality of the evidence as low. Thus, we judged that the indirect evidence obtained from this review does not suffice to consider that CHM interventions have an impact on COVID-19. Five observational studies were also found pointing to a benefit associated with the use of CHMs. All these studies were uncontrolled designs, with small sample sizes and poor reporting, and they do not allow determining the effects of a health care intervention.

This review highlights the need of RCTs to determine the benefits and harms of CHMs for the treatment of COVID-19. A total of 52 ongoing trials evaluating the effects of different Chinese herbal products for the treatment of COVID-19 were found. This is an important step to get solid findings. All the studies but one will take place in China and 40 out of the 52 seem randomized designs.

Potential biases in the review process
The main limitation of this review is its narrative approach. However, the authors tried to state a clear set of objectives with predefined eligibility criteria for the studies. In this line, a review question was formulated according to the PICO-D format, that is, defining the participants, interventions, comparators, outcomes, and the eligible study designs. Also, it was attempted to reduce the risk of publication bias, as demonstrated hereunder.

It is acknowledged that this review did not search in several relevant electronic databases, such as Embase or the Chinese Biomedical Literature. However, MEDLINE (through PubMed) and CENTRAL were consulted (the latter is the largest database of trials in the world). Also, the authors were able to translate documents from Chinese and Korean to English, and contacted Chinese experts asking for relevant trials in the field.

Another weakness of this review is that a direct search of the ChiCTR for ongoing trials was not done. However, ChiCTR is indexed in the WHO ICTRP platform, which, in turn, can be accessed from the Cochrane COVID-19 Study Register, the tool consulted in this review.

The Institute for Complementary and Integrative Medicine (Zurich University Hospital) hosts Cochrane Complementary
| Herbal product | Presentation | Study design | Sample size | Identification |
|----------------|--------------|--------------|-------------|----------------|
| Oral administration | | | | |
| Ba Bao Dan | Capsules | RCT | 40 | ChiCTR2000029769 |
| Diammonium glycyrrhizinate | Capsules | RCT | 60 | ChiCTR2000029768 |
| | Capsules | Non-RCT | 100 | ChiCTR2000030490 |
| Escin | Not reported | Non-RCT | 120 | NCT04322344 |
| Exocarpium citri grandis | Not reported | RCT | 128 | ChiCTR2000030804 |
| Honeysuckle decoction Oral liquid | Oral liquid | RCT | 110 | ChiCTR2000029822 |
| | Oral liquid | RCT | 300 | ChiCTR2000029954 |
| Huai Er | Granules | RCT | 550 | NCT04291053 |
| Huashi Baidu | Granules | RCT | 204 | ChiCTR2000030988 |
| Huatan Zhike pediatric | Granules | RCT | 100 | ChiCTR2000030022 |
| Lianhua Qingwen | Capsule/granules | RCT | 240 | ChiCTR2000029433 |
| | Capsule/granules | RCT | 240 | ChiCTR2000029434 |
| Liu Shen Wan (LSW) | Not reported | RCT | 96 | ChiCTR2000030469 |
| Liu Shen | Capsule | RCT | 40 | ChiCTR2000029993 |
| Qingfei Paidu | Not reported | RCT | 180 | ChiCTR2000029855 |
| Qingwen Baidu Yin | Granules | RCT | 20 | ChiCTR2000030166 |
| Qingyi No. 4 compound | Granules | RCT | 200 | ChiCTR2000029947 |
| Jing Yin | Granules | RCT | 300 | ChiCTR2000030255 |
| Jingye Baidu | Granules | RCT | 120 | ChiCTR2000029755 |
| Kang Guan Nos. 1–3 | Oral solution | RCT | 120 | ChiCTR2000030215 |
| KeSu Ting (group 1) or Ke Qing (group 2) | Syrup | RCT | 72 | ChiCTR2000029991 |
| Kang Binguo | Granules | RCT | 160 | ChiCTR2000029781 |
| Maxing Ganshi decoction | Not reported | RCT | 100 | ChiCTR2000030522 |
| Shenling Baizhu | Powder | Non-RCT | 120 | ChiCTR2000029956 |
| Shuang Huang Lian | Oral solution | RCT | 400 | ChiCTR2000029605 |
| Tan Re Qing (TRQ) | Capsules | RCT | 72 | ChiCTR2000029813 |
| Traditional Chinese Medicine formula nr. 1 or 2 or 3 or 4 or 5 or 6 | Not reported | RCT | 400 | ChiCTR2000030923 |
| Traditional Chinese Medicine Formula No. 1 and 2 (group 1) or Ganke Shuangqing (group 2) or Shuang Huang Lian (group 3) | Not reported | RCT | 480 | ChiCTR2000030003 |
| Traditional Chinese Medicine decoction (Huoxiang 9 g, Magnolia 9 g, Yinhua 9 g, Atractylodes 9 g, Cicada 6 g, Su Ye 6 g, Poria 15 g, Huai yam 15 g) | Not reported | RCT | 10 | ChiCTR2000029517 |
| Traditional Chinese Medicine decoctions | Not reported | Non-RCT | 150 | NCT04251871 |
| | RCT | 100 | ChiCTR2000029461 |
| | RCT | 120 | ChiCTR2000029439 |
| | RCT | 100 | ChiCTR2000029493 |
| | RCT | 60 | ChiCTR2000030751 |
| | RCT | 300 | ChiCTR2000029869 |
| | RCT | 300 | ChiCTR2000030836 |
| | RCT | 100 | ChiCTR2000030479 |
| | RCT | 116 | NCT04310865 |
| | RCT | 300 | NCT04278963 |
| Traditional Mongolian medicine Truncation and torsion formula | Not reported | RCT | 300 | NCT04275388 |
| Yiqi Huashi Jiedu Fang | Not reported | RCT | 100 | ChiCTR2000030479 |
| Yinhu Qingwen | Granules | RCT | 116 | NCT04310865 |
| | Granules | RCT | 300 | NCT04278963 |
| Injection | Non-RCT | 60 | ChiCTR2000029589 |
| ReDuNing (RDN) | RCT | 160 | ChiCTR2000029780 |
| Shenqi Fuzheng | RCT | 160 | ChiCTR2000029780 |
| Shenfu | RCT | 300 | ChiCTR2000030043 |
| Sodium Aescinate injection | RCT | 90 | ChiCTR2000029742 |
| Tan Re Qing (TRQ) | Non-RCT | 72 | ChiCTR2000029432 |
| Xiyian Ping | RCT | 348 | ChiCTR2000030117 |
| | RCT | 238 | ChiCTR2000029756 |
| | RCT | 80 | ChiCTR2000030218 |
| | RCT | 348 | NCT04275388 |
| Xuebi Jing | RCT | 60 | ChiCTR2000030388 |
| | Non-RCT | 400 | ChiCTR2000029381 |
| Zedoary turmeric oil | RCT | 60 | ChiCTR2000030518 |

RCT, randomized controlled trial.
Medicine Switzerland, a satellite group of Cochrane Complementary Medicine. Cochrane Complementary Medicine is a field established in Cochrane in 1996 to support and promote systematic reviews of complementary, alternative, and integrative therapies and to function as a link between Cochrane, a worldwide organization that prepares systematic reviews of all kinds of health care therapies, and practitioners, researchers, and consumers with an interest in complementary medicine.” On April 7, 2020, Cochrane launched its COVID-19 Study Register to support rapid evidence synthesis by all systematic review producers. This tool was used to identify ongoing RCTs on CHMs for the treatment of COVID-19. This register was helpful as it allowed searching the ongoing trials on COVID-19 from one source.

It is also acknowledged that the search strategy in MEDLINE focused on Chinese herbal products, the topic of this review. This might have hampered the identification of relevant guidelines or studies on herbal products used in other Asian countries and not categorized as “Chinese.” However, it is still considered that this search strategy allowed identifying the most relevant evidence. First, because the search strategy in MEDLINE also used MeSH terms related to herbal products in general, and not only the Chinese products (“Oriental Traditional Medicine” and “Medicinal Plants”). Second, other sources than MEDLINE were searched, such as databases collecting guidelines (e.g., Trip Medical Database) or the bibliographies of relevant documents.

Agreements and disagreements with other studies or reviews

This review did not find reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. This conclusion is consistent with previous analyses that concluded that, to date, there is no evidence of any specific CHM intervention for the treatment of patients with COVID-19. This conclusion is consistent with other studies or reviews.

The lack of reliable evidence of the benefits of CHMs in patients with COVID-19 does not support the expectations that CHMs would be a valuable treatment against COVID-19. For example, there is no evidence on the effects of CHMs on critical outcomes in the context of the current pandemic, such as the length of hospital stay. A reduced length of stay of patients with COVID-19 is an essential outcome to support decision making in overloaded health care facilities worldwide.

However, the use of CHMs to contain SARS-CoV-2 has been promoted in China, and the Chinese and South Korean guidelines have endorsed the use of CHMs as a treatment option for COVID-19. Besides, CHMs have been widely used in China to treat patients with COVID-19. For example, Yin Qiao powder, Huo pu Xialing decoction, Maxing Shigan decoction, Liang Ge powder, Qingwen Baidu decoction, and Da Yuan decoction have been widely prescribed for the treatment of COVID-19. Also, ~85% of the total confirmed COVID-19 cases may have received TCM interventions. In fact, Qingfei Paidu Tang is recommended in the Chinese and Korean guidelines.

Although CHMs have been proposed in China as a treatment option in patients with COVID-19, its efficacy and safety still need to be confirmed by well-designed clinical studies. The website of the National Center for Complementary and Integrative Health in the United States explicitly states that “There is no scientific evidence that any of these alternative remedies can prevent or cure the illness caused by this virus.” Besides, as this site highlights, some alternative treatments may not be safe to consume. Gray and Belessis brought up the point that the use of CHMs to treat SARS-CoV-2 may cause harm due to its potential for iatrogenic lung injury (interstitial pneumonia). Also, the interactions of the herbs with conventional treatment should be carefully assessed. Therefore, the benefit–risk balance for CHMs needs to be carefully evaluated and acknowledged.

All the Chinese guidelines evaluated in this overview recommend herbal medicines for the management of COVID-19, and health care professionals in China have used them frequently in patients with COVID-19. Interestingly, as already stated, only 12% of the Chinese biomedical clinical guidelines for other diseases recommended CHMs. This gap might be explained by the fact that there has not been an effective treatment against COVID-19 so far. Nevertheless, extreme situations such as COVID-19 seem to change the processes to generate, synthesize, and implement the evidence, and how all the relevant stakeholders involved (policy makers, guideline developers, and health care professionals) contribute. A deeper understanding of how the evidence ecosystem adapts to a pandemic might be an interesting topic of future research.

This review highlights that so far no recommendation of CHMs in the Chinese guidelines was developed according to transparent, explicit, and rigorous methods. This finding is compatible with the results of another study, which found that only 9% (7/74) of the Chinese clinical guidelines providing recommendations on TCMs had followed a system to grade the evidence and develop the recommendations. This review found a high number of trials (n = 52) that are currently running to determine the effectiveness of CHMs for the treatment of COVID-19. However, 12 of these trials will be nonrandomized, and only 5 trials will have a sample size of at least 400 participants. Small samples imply that most of the ongoing trials will not be powered enough to detect differences in the primary outcome of the study. Besides, 27.5% of the trials evaluating oral CHMs did not report the form of administration (capsule, granules, tablets, liquid, etc.). Also, nine additional ongoing trials were found with a poor reporting that prevented knowing whether they were planning to evaluate CHMs. These findings are broadly compatible with the results of previous studies, which highlighted that the COVID-19 trials on TCM registered so far were poorly reported and small sized, thus they might not provide reliable information for decision making.

Zhu RF, et al. Preprint of a not peer-reviewed article. MedRxiv. 2020. Online document at: www.medrxiv.org/content/10.1101/2020.03.01.20029611v2, accessed March 19, 2020.

Qiu R, et al. Preprint of a not peer-reviewed article. MedRxiv. 2020. Online document at: www.medrxiv.org/content/10.1101/2020.03.04.20031401v1, accessed March 19, 2020.
Conclusions

Implications for practice

To the authors’ knowledge, only the Chinese and the South Korean guidelines recommend CHMs as a treatment option for patients with COVID-19. These guidelines exclusively base their recommendations on the consensus of experts. Clinical guidelines or health authorities from other countries do not provide advice on CHMs.

There is currently no reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19. No completed RCTs on CHMs were found for the treatment of patients with COVID-19. According to the evidence evaluated in this review, a Cochrane review of CHMs for SARS and five uncontrolled observational studies, the effects of CHMs for COVID-19 are unknown.

Implications for research

Well-designed and adequately powered RCTs to determine the effects (benefits and harms) of CHMs in patients with COVID-19 are needed. A high number of RCTs of different herbal products are being conducted in China.

Acknowledgments

The authors thank Hospital Universitario Ramón y Cajal (Madrid) for the provision of full text articles. They also thank Jianping Liu for providing information on relevant studies and guidelines.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

No funding was received for this article.

References

1. Hu J, Zhang J, Zhao W, et al. Cochrane systematic reviews of Chinese herbal medicines: An overview. PLoS One 2011;6:e28696.
2. Park HL, Lee HS, Shin BC, et al. Traditional medicine in China, Korea, and Japan: A brief introduction and comparison. Evidence Based Complement Altern Med 2012;2012:429103.
3. World Health Organization. Regional Office for the Western Pacific. The regional strategy for traditional medicine in the Western Pacific (2011–2020). Manila: WHO Regional Office for the Western Pacific, 2012.
4. World Health Organization. ICD-11 International Classification of Diseases 11th Revision 2020. Online document at: https://icd.who.int/en, accessed April 22, 2020.
5. Ren J, Li X, Sun J, et al. Is traditional Chinese medicine recommended in Western medicine clinical practice guidelines in China? A systematic analysis. BMJ Open 2015;5:e006572.
6. Ross CL. Integral healthcare: The benefits and challenges of integrating complementary and alternative medicine with a conventional healthcare practice. Integr Med Insights 2009;4:13–20.
7. Zollman C, Vickers A. ABC of complementary medicine. Complementary medicine in conventional practice. BMJ 1999;319:901–904.
8. Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev 2012;10:CD004882.
9. Yang Q, Zhao T, Sun C, et al. New thinking in the treatment of 2019 novel coronavirus pneumonia. Complement Ther Clin Pract 2020;39:101131.
10. Denis M. Overview of information available to support the development of medical countermeasures and interventions against COVID-19: Rega Institute for Medical Research. 2020. Online document at: https://rega.kuleuven.be/it/pdf_corona, accessed March 19, 2020.
11. Zhang DH, Wu KL, Zhang X, et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integ Med 2020;18:152–158.
12. Weng JR, Lin CS, Lai HC, et al. Antiviral activity of Sambucus Formosana Nakai ethanol extract and related phenolic acid constituents against human coronavirus NL63. Virus Res 2019;273:197767.
13. WHO. SARS: Clinical trials on treatment using a combination of Traditional Chinese Medicine and Western Medicine. 2004. Online document at: https://apps.who.int/medicinedocs/en/d/d6170e/3.html, accessed March 19, 2020.
14. University Hospital Zurich. Institute for Complementary and Integrative Medicine. 2020. Online document at: http://www.en.iki.usz.ch/Pages/default.aspx, accessed April 22, 2020.
15. Liu P, Cao Y, Qiao X. [Clinical study on shenmai injection in promoting postoperative recovery in patients with breast cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000;20:328–329.
16. Cochrane. COVID-19 study register. 2020. Online document at: https://covid-19.cochrane.org/, accessed April 23, 2020.
17. Thomson Reuters. Endnote reference management software (version X7.8). Thomson Reuters, 2016.
18. Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed Coronavirus disease (COVID-19). 2020. Online document at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html, accessed March 18, 2020.
19. Centers for Disease Control and Prevention (CDC). Information for clinicians on investigational therapeutics for patients with COVID-19. 2020. Online document at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html, accessed April 22, 2020.
20. Infectious Diseases Society of America Guidelines (IDSA). Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2020. Online document at: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/, accessed April 22, 2020.
21. National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) treatment guidelines. 2020. Online document at: https://covid-19.cdc.gov/project/ncov/hcp/clinical-guidance-advisory/covid-19-algorithm.pdf, accessed April 22, 2020.
22. The American College of Obstetrician and Gynecologists, Society for Maternal-Fetal Medicine. Outpatient assessment and management for pregnant women with suspected or confirmed novel Coronavirus (COVID-19). 2020. Online document at: https://www.acog.org/-/media/project/acog/acogorg/files/pdfs/practice-advisory/covid-19-algorithm.pdf, accessed April 22, 2020.
23. Health Protection Scotland (HPS). Novel coronavirus (COVID-19) guidance for primary care management of patients in primary care Including general dental practice, general medical practice, optometry and pharmacy Version 11.1 (version 16 April 2020). 2020. Online document at: https://
28. Government of Canada. Infection prevention and control
27. British Columbia Centre for Disease Control (BCCDC).
26. Public Health England. COVID-19: Guidance for health
24. National Institute for Health and Care Excellence (NICE).
34. Australia National COVID-19 Clinical Evidence Taskforce.
33. The First Affiliated Hospital, Zhejiang University School of
32. National Health Commission (NHC) National Administra-
31. National Health Commission (NHC), National Adminis-
30. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for
29. Government of Canada. Infection prevention and control
28. Government of Canada. Infection prevention and control
27. British Columbia Centre for Disease Control (BCCDC).
26. Public Health England. COVID-19: Guidance for health
25. National Institute for Health and Care Excellence (NICE).
24. National Institute for Health and Care Excellence (NICE).
23. Government of Canada. Infection prevention and control
22. Australian National COVID-19 Clinical Evidence Taskforce.
21. The First Affiliated Hospital, Zhejiang University School of
20. Online document at: https://www.nice.org.uk/guidance/ng163, accessed April 22, 2020.
19. Ministry of Health of Malaysia. Novel coronavirus
18. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for
17. Government of Canada. Infection prevention and control
16. British Columbia Centre for Disease Control (BCCDC).
15. National Health Commission (NHC) National Administra-
14. Robert Koch Institute. Notes on detection, diagnostics and
13. Alhazzani W, Moller MH, Arabi YM, et al. Surviving
12. European Centre for Disease Prevention and Control
11. World Health Organization (WHO). Preparedness, preven-
10. World Health Organization (WHO). Clinical management of
9. Ministry of Health of Malaysia. Novel coronavirus
8. Alhazzani W, Moller MH, Arabi YM, et al. Surviving
7. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for
6. National Health Commission (NHC) National Administra-
5. National Health Commission (NHC) National Administra-
4. National Health Commission (NHC), National Administra-
3. National Health Commission (NHC), National Administra-
2. National Health Commission (NHC), National Administra-
1. National Health Commission (NHC), National Administra-
2. National Health Commission (NHC), National Administra-
1. National Health Commission (NHC), National Administra-
20. Online document at: www.who.int/publications-detail/clinical-
19. Government of Canada. Infection prevention and control
18. Government of Canada. Infection prevention and control
17. Interim Guidance: Public Health Management of cases and
16. Interim Guidance: Public Health Management of cases and
15. Interim Guidance: Public Health Management of cases and
14. Interim Guidance: Public Health Management of cases and
13. Interim Guidance: Public Health Management of cases and
12. Interim Guidance: Public Health Management of cases and
11. Interim Guidance: Public Health Management of cases and
10. Interim Guidance: Public Health Management of cases and
9. Interim Guidance: Public Health Management of cases and
8. Interim Guidance: Public Health Management of cases and
7. Interim Guidance: Public Health Management of cases and
6. Interim Guidance: Public Health Management of cases and
5. Interim Guidance: Public Health Management of cases and
4. Interim Guidance: Public Health Management of cases and
3. Interim Guidance: Public Health Management of cases and
2. Interim Guidance: Public Health Management of cases and
1. Interim Guidance: Public Health Management of cases and
20. Online document at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/interim-guidance-acute-healthcare-settings.html, accessed March 18, 2020.
19. Online document at: www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid%20Manual/Chap
ter%201%20-%20VCD/2019-nCoV-Interim_Guidelines.pdf, accessed April 22, 2020.
18. Online document at: https://www.nice.org.uk/guidance/ng163, accessed April 22, 2020.
17. Online document at: https://covid19evidence.net.au/documents/1_covid-19-guidance-for-primary-care.pdf, accessed April 22, 2020.
16. Online document at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.
15. Online document at: http://akomnews.com/bbs/board.php?bo_table=news&wr_id=38324, accessed May 14, 2020.
14. Online document at: www.moh.gov.my/moh/resources/Penerbitan/Garis%20PanduanCOVID19/Annex_35_GUIDE_LINES_OF_INFECTION_CONTROL_AND_CLINICAL_MANAGEMENT_OF_SARI_PNEUMONIA_TRO_COVID-19.pdf, accessed April 22, 2020.
13. Online document at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.
12. Online document at: https://www.ecdc.europa.eu/en/novel-coronavirus-china, accessed March 17, 2020.
11. Online document at: www.moh.gov.my/moh/resources/Penerbitan/Garis%20PanduanCOVID19/Annex_35_GUIDE_LINES_OF_INFECTION_CONTROL_AND_CLINICAL_MANAGEMENT_OF_SARI_PNEUMONIA_TRO_COVID-19.pdf, accessed April 22, 2020.
10. Online document at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.
9. Online document at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.
8. Online document at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.
7. Hu Y, Zhou X. Prevention and control of COVID-19 in prisons and other places of detention Interim guidance. 2020. Online document at: www.euro.who.int/__data/assets/pdf_file/0019/434026/Preparedness-prevention-and-control-of-COVID-19-in-prisons.pdf?ua=1, accessed April 22, 2020.
48. Hou Y, He X, Zhang Y, et al. Integrated traditional Chinese and Western medicine for 34 patients with severe SARS. Chin J Integr Tradit West Med 2004;24:81–82.
49. Li X, Sun J, Zhang Z, et al. Clinical study of integrated traditional Chinese and Western medicine for patients with severe acute respiratory syndrome on recovery stage. Beijing J TCM 2004;23:26–27.
50. Ren A, Zhang S, Wang B, et al. Clinical study on treatment of severe acute respiratory syndrome by integrative Chinese and Western medicine. Chin J Integr Tradit West Med 2004;24:112–114.
51. Zhang L, Wu W, Hou Y, et al. Integrated Chinese and Western medicine for 30 patients with SARS. J Tradit Chin Med 2004;45:675–677.
52. Zhang; SN. Clinical effect of integrated traditional Chinese and Western medicine for lung filtrate absorption of patients with severe acute respiratory syndrome. Chin Gen Pract 2003;6:576.
53. Li Z, Bao F, Li Q, et al. Clinical study on treatment of severe acute syndrome with integrated traditional Chinese and Western medicine. Chin J Integr Tradit West Med Intensive Crit Care 2004;10:214–216.
54. Li J, Li S, Du L, et al. Clinical study on treatment of severe acute respiratory syndrome with integrative Chinese and Western medicine approach. Chin J Integr Tradit West Med 2004;24:28–31.
55. Bian Y, Qi W, Song Q, et al. Evaluation on the effect of integrative medical treatment on quality of life of rehabilitation stage in 85 patients with SARS. Chin J Integr Tradit West Med 2003;23:358–360.
56. Zhang Q, Huang J, Liu S, et al. Clinical study of integrated Chinese and Western medicine for quality of life improvements of SARS patients at recovery stage. Beijing J TCM 2004;23:22–24.
57. Ni L, Zhou L, Zhou M, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front Med 2020;14:210–214.
58. Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64–68.
59. Xu K, Cai H, Shen Y, et al. [Management of corona virus disease-19 (COVID-19): The Zhejiang experience.] Zhejiang da xue xue bao. Yi xue ban 2020;49:0.
60. Zhang AH, Zhu YX. One highly suspected case of novel coronavirus pneumonia treated by Integrated Traditional Chinese and Western medicine and nucleic acid analysis, Tianjin Journal of Traditional Chinese Medicine. 2020. Online document at: http://kns.cnki.net/kcms/detail/12.1349.R.20200227.0909.004.html, accessed March 17, 2020.
61. Biki E. Comments on “Traditional Chinese medicine for COVID-19 treatment”: PubPeer: The online Journal Club. 2020. Online document at: https://pubpeer.com/publications/5E708B08D398F43E6AA5EE74E6E4E3, accessed March 17, 2020.
62. Biki E. Some critical notes on a COVID-19 TCM paper Science Integrity Digest, 2020. Online document at: https://scienceintegritydigest.com/2020/03/09/some-critical-notes-on-a-covid-19-paper/, accessed March 17, 2020.
63. WHO. Overview of the types/classes of candidate therapeutics. 2020. Online document at: https://www.who.int/blueprint/priority-diseases/key-action/overview-ncov-therapeutics.pdf?ua=1, accessed March 19, 2020.

64. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends 2020;14:69–71.
65. Cochrane Complementary Medicine Switzerland. 2020. Online document at: https://cam.cochrane.org/about-us/oursatellite-groups, accessed April 23, 2020.
66. Cochrane Complementary Medicine. 2020. Online document at: https://cam.cochrane.org/, accessed April 23, 2020.
67. Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western Medicine for the management of 2019 novel Coronavirus disease. Am J Chin Med 2020;1–26.
68. Cui HT, Li YT, Guo LY, et al. Traditional Chinese medicine for treatment of coronavirus disease 2019: A review. Tradit Med Res 2020;5:65–73.
69. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019-New Coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci 2020;16:1708–1717.
70. Luo H, Tang QL, Shang YX, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020;26:243–250.
71. Ang L, Lee HW, Choi JY, et al. Herbal medicine and pattern identification for treating COVID-19: A rapid review of guidelines. Integr Med Res 2020;9:100407.
72. Fan T, Chen Y, Bai Y, et al. [Analysis of medication characteristics of traditional Chinese medicine in treating coronavirus disease-19 based on data mining]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49:0.
73. U.S. National Center for Complementary and Alternative Medicine. In the news: Coronavirus and “alternative” treatments. 2020. Online document at: https://nccih.nih.gov/health/in-the-news-in-the-news-coronavirus-and-alternative-treatments, accessed March 19, 2020.
74. Coghlan ML, Maker G, Crighton E, et al. Combined DNA, toxicological and heavy metal analyses provides an auditing toolkit to improve pharmacovigilance of traditional Chinese medicine (TCM). Sci Rep 2015;5:17475.
75. Gray PE, Belessis Y. The use of Traditional Chinese Medicine to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res 2020;156:104776.
76. Sakamoto O, Ichikado K, Kohrogi H, Suga M. Clinical and CT characteristics of Chinese medicine-induced acute respiratory distress syndrome. Respirology 2003;8:344–350.
77. Chan E, Tan M, Xin J, et al. Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel 2010;13:50–65.
78. Heneghan C, Aronson J, Ferner R, DeVito N. COVID-19 registered trials—and analysis: The centre for evidence-based medicine. 2020. Online document at: https://www.ccbm.net/oxford-covid-19/covid-19-registered-trials-and-analysis/, accessed March 17, 2020.

Address correspondence to:
Jürgen Barth, PhD
Institute for Complementary and Integrative Medicine
University Hospital Zürich
Sonnergasse 6
Zürich CH-8091
Switzerland
E-mail: mail@juergen-barth.de
Appendix

Appendix A1. Sources Consulted and Search Strategies

Electronic Databases (All accessed April 23, 2020)

MEDLINE (through PubMed)

| Query                                                                 | Records |
|-----------------------------------------------------------------------|---------|
| 1 Search “Drugs, Chinese Herbal”[Mesh]                               | 42,843  |
| 2 Search “Medicine, Chinese Traditional”[Mesh]                        | 18,663  |
| 3 Search “Medicine, East Asian Traditional”[Mesh]                     | 21,720  |
| 4 Search Plants, Medicinal/                                          | 72,774  |
| 5 Search chinese herb* (Ti, ab or keywords)                           | 49,329  |
| 6 Search (((“Drugs, Chinese Herbal”[Mesh]) OR “Medicine, Chinese Traditional”[Mesh]) OR “Medicine, East Asian Traditional”[Mesh]) OR Plants, Medicinal/) OR chinese herb* (Ti, ab or keywords) | 129,224 |
| 7 Search coronavirus covid-19 (Ti, ab or keywords)                    | 3393    |
| 8 Search “Coronavirus disease 2019” (Ti, ab or keywords)              | 985     |
| 9 Search “2019 novel coronavirus” (Ti, ab or keywords)                | 440     |
| 10 Search “2019-nCoV” (Ti, ab or keywords)                            | 533     |
| 11 Search ((coronavirus covid-19) OR “Coronavirus disease 2019”) OR “2019 novel coronavirus”) OR “2019-nCoV” (Ti, ab or keywords) | 3556    |
| 12 Search #6 AND #11                                                  | 35      |

The Cochrane Library, which contains the following sources:

- The Cochrane Central Register of Controlled Trials (CENTRAL) 2020, Issue 3 (which contains the Acute Respiratory Infection Group’s Specialised Register)
- Cochrane Database of Systematic reviews

| Query                                                                 | Records |
|-----------------------------------------------------------------------|---------|
| 1 Search coronavirus covid-19 (Ti, ab or keywords)                     | 3393    |
| 2 Search “Coronavirus disease 2019” (Ti, ab or keywords)              | 985     |
| 3 Search novel near coronavirus (Ti, ab or keywords)                   | 440     |
| 4 Search nCoV (Ti, ab or keywords)                                    | 533     |
| 5 Search [OR #1–#4] Results in Cochrane Database of Systematic Reviews | 3       |
| Results in CENTRAL                                                   | 56      |

2. Other Sources

a. Epistemonikos (“Evidence for COVID”)
b. Tripdatabase
c. MEDBOX Rapid Response Toolbox
d. Evidence Aid: Coronavirus (COVID-19) Evidence Collection
e. UpToDate
f. Dynamed
h. Websites of relevant organizations
1. Centers for Disease Control and Prevention (CDC)
2. European Centre for Disease Prevention and Control (ECDC)
3. The National Institute for Health and Care Excellence (NICE)
4. National University of Singapore Saw Swee Hock School of Public Health
5. U.S. National Center for Complementary and Alternative Medicine
6. JAMA resources on COVID-19
7. CEBM resources on COVID-19
i. Contact of experts in the field
   Experts in China were contacted asking for relevant studies or guidelines.
j. Bibliographies of systematic and narrative reviews

3. Trial Registries (To Identify Ongoing Studies)

The Cochrane COVID-19 Study Register was consulted.

| Query                                                                 | Records |
|-----------------------------------------------------------------------|---------|
| 1 Study type: interventional                                          | 33      |
| 2 Study aim: treatment management                                     | 3       |
| 3 Intervention assignment: randomized or unclear                      | 27      |
| 4 Search [OR #1–#4]                                                  | 521     |

The 521 records to endnote were imported, where the selection process was performed by reading the titles of all records. Besides, searches of specific terms in endnote were implemented to check that no relevant study was missing. The following terms were used: Traditional OR Chinese OR Herb or TCM OR decoction OR Qingyi OR Western medicine OR Feidian OR glycyrrhiza OR Lian-Hua OR Huo-Shen OR Xiyaping OR Kang-Bing-Du OR Zedoary OR turmeric OR oil OR Xue-Bi-Jing OR Shen-Fu OR Capsule OR granule.

Appendix A2. Documents Consulted

Guidelines \(n = 25\)

International \(n = 4\)

1. World Health Organization (WHO), A1
2. World Health Organization (WHO), A2
3. European Centre for Disease Prevention and Control (ECDC), A3

(Appendix continues →)
4. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)\textsuperscript{A5}

\textbf{America (n=8)}

Canada (n=3)

1. Government of Canada.\textsuperscript{A6}
2. Government of Canada.\textsuperscript{A6}
3. British Columbia Centre for Disease Control (BCCDC).\textsuperscript{A7}

United States (n=5)

1. National Institutes of Health (NIH).\textsuperscript{A8}
2. CDC.\textsuperscript{A9}
3. CDC.\textsuperscript{A10}
4. IDSA.\textsuperscript{A11}
5. American Coleageue of Obstetrician and Gynecologists, Society for Maternal-Fetal Medicine.\textsuperscript{A12}

\textbf{Asia (n=6)}

China (n=3)

1. National Health Commission (NHC), National Administration of Traditional Chinese Medicine, Sixth Edition.\textsuperscript{A13}
2. Jin et al.\textsuperscript{A14}
3. The First Affiliated Hospital, Zhejiang University School of Medicine.\textsuperscript{A15}

Malaysia (n=1)

1. Ministry of Health of Malaysia.\textsuperscript{A16}

South Korea (n=2)

1. South Korean physicians treatment guidelines.\textsuperscript{A17}
2. Traditional medicine guidelines on the prevention and treatment of COVID-19, first edition, February 25, 2020 (the Association of Korean Medicine and the Korean Association of Traditional Pulmonary Medicine)\textsuperscript{A18}

\textbf{Europe (n=5)}

United Kingdom (n=4)

1. Public Health England.\textsuperscript{A19}
2. Health Protection Scotland (HPS).\textsuperscript{A20}
3. National Institute for Health and Care Excellence (NICE).\textsuperscript{A21}
4. National Institute for Health and Care Excellence (NICE).\textsuperscript{A22}

Germany (n=1)

1. Robert Koch Institute.\textsuperscript{A23}

\textbf{Oceania (n=2)}

Australia (n=2)

1. The Australian and New Zealand Intensive Care Society (ANZICS).\textsuperscript{A24}

2. Australia National COVID-19 Clinical Evidence Taskforce.\textsuperscript{A25}

\textbf{Systematic Reviews (n=1)}

A Cochrane review\textsuperscript{A26} was found published in 2012 assessing the effectiveness and safety of Chinese herbs combined with conventional medicines versus conventional medicines alone for patients with “severe acute respiratory syndrome” (SARS). SARS was recognized in 2003 and caused by another coronavirus, known as SARS CoV. Another systematic review has proposed a system to identify herbal components of TCM that may have an effect on COVID-19.\textsuperscript{A27}

\textbf{Evidence Summaries (n=3)}

1. BMJ Best practice: Coronavirus disease 2019 (COVID-19)\textsuperscript{A28}
2. UpToDate. Coronavirus disease 2019 (COVID-19) (version March 16, 2020)\textsuperscript{A29}
3. DynaMed. COVID-19 (Novel Coronavirus)\textsuperscript{A30}

\textbf{Randomized Controlled Trials (n=0)}

No finished randomized controlled trials was found to support specific CAM treatments in suspected or confirmed cases of COVID-19.

\textbf{Narrative Reviews (n=11)}

1. National University of Singapore, Saw Swee Hock School of Public Health.\textsuperscript{A31}
2. Li and De Clercq.\textsuperscript{A32}
3. Chan et al.\textsuperscript{A33}
4. Cui et al.\textsuperscript{A34}
5. Lu.\textsuperscript{A35}
6. Luo et al.\textsuperscript{A36}
7. Zhang et al.\textsuperscript{A37}
8. Denis.\textsuperscript{A38}
9. Gray and Belessis.\textsuperscript{A39}
10. Han Ru et al.\textsuperscript{A40}
11. Yang et al.\textsuperscript{A41}

\textbf{Case Reports (n=5)}

1. Wang et al.\textsuperscript{A42}
2. Ni et al.\textsuperscript{A43}
3. Xu et al.\textsuperscript{A44}
4. Yang et al.\textsuperscript{A45}
5. Ren et al.\textsuperscript{A46}

\textbf{Other Studies (n=3)}

1. Zhang et al.\textsuperscript{A27}
2. WHO.\textsuperscript{A47}
3. Lu.\textsuperscript{A35}

\textbf{Appendix References}

A1. World Health Organization (WHO), Clinical management of severe acute respiratory infection when novel
coronavirus (nCoV) infection is suspected: interim guidance. 2020. Online document at https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, accessed March 17, 2020.

A2. World Health Organization (WHO). Preparedness, prevention and control of COVID-19 in prisons and other places of detention Interim guidance. 2020; www.euro.who.int/_data/assets/pdf_file/0019/434026/Preparedness-prevention-and-control-of-COVID-19-in-prisons.pdf?ua=1, accessed April 22, 2020.

A3. European Centre for Disease Prevention and Control (ECDC). COVID-19. 2020. Online document at https://www.ecdc.europa.eu/en/novel-coronavirus-china, accessed March 18, 2020.

A4. Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46(6):e440–e469.

A5. Government of Canada. Infection prevention and control for coronavirus disease (COVID-19): Interim guidance for acute healthcare settings. 2020. Online document at https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/interim-guidance-acute-healthcare-settings.html, accessed March 18, 2020.

A6. Government of Canada. Clinical management of patients with moderate to severe COVID-19: Interim guidance. 2020. Online document at https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents.html, accessed April 22, 2020.

A7. British Columbia Centre for Disease Control (BCCDC). Interim Guidance: Public Health Management of cases and contacts associated with novel coronavirus (COVID-19) in the community. 2020. www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%201%20-%20CD%2019-nCoV-Interim_Guidelines.pdf, accessed April 22, 2020.

A8. National Institutes of Health (NIH). Coronavirus Disease 2019 (COVID-19) treatment guidelines. 2020. Online document at https://covid19treatmentguidelines.nih.gov/, accessed April 22, 2020.

A9. Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed Coronavirus disease (COVID-19). 2020. Online document at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html, accessed March 18, 2020.

A10. Centers for Disease Control and Prevention (CDC). Information for clinicians on investigational therapeutics for patients with COVID-19. 2020. Online document at https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html, accessed April 22, 2020.

A11. Infectious Diseases Society of America Guidelines (IDSA). Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. 2020. Online document at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/, accessed April 22, 2020.

A12. The American Colleague of Obstetrician and Gynecologists, Society for Maternal-Fetal Medicine. Outpatient assessment and management for pregnant women with suspected or confirmed novel Coronavirus (COVID-19). 2020. Online document at https://www.acog.org/media/project/acf/acf007754fddfbf.pdf?disk1=true&disk2=true&disk3=true&disk4=true&disk5=true&disk6=true&disk7=true&disk8=true&disk9=true&disk10=true, accessed April 22, 2020.

A13. National Health Commission (NHC) National Administration of Traditional Chinese Medicine. Guidance for Coronavirus Disease 2019: Prevention, control, diagnosis and management. People’s Republic of China: People’s Medical Publishing House, 2020.

A14. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7:4.

A15. The First Affiliated Hospital, Zhejiang University School of Medicine. Handbook of COVID-19 prevention and treatment. 2020. Online document at https://video.intl.alicdn.com/Handbook%20of%20COVID-19%20Prevention%20and%20Treatment.pdf?spm=a3c0i.14138300.8102420620 .download.6df3647f4EeWKYkfile=Handbook%20of%20COVID-19%20Prevention%20and%20Treatment.pdf, accessed March 19, 2020.

A16. Ministry of Health of Malaysia. Novel Coronavirus (COVID-19) Management In Malaysia: Guidelines of infection control and clinical management of severe acute respiratory infections (SARI)/Pneumonia COVID-19. 2020. www.moh.gov.my/moh/resources/Penerbitan/Garis%20Panduan/COVID19/Annex_35_GUIDELINES_OF_INFECTION_CONTROL_AND_CLINICAL_MANAGEMENT_OF_SARI_PNEUMONIA_TRO_COVID19.pdf, accessed April 22, 2020.

A17. Sung-sun K. Physicians work out treatment guidelines for coronavirus. 2020. Online document at www.koreabiomed.com/news/articleView.html?idxno=7428, accessed March 17, 2020.

A18. Association of Korean Medicine, Korean Association of Traditional Pulmonary Medicine. Coronavirus Infection Oriental Medicine Clinical Practice Guidelines. 2020. Online document at http://akomnews.com/bbs/board.php?bo_table=news&wr_id=38324, accessed May 14, 2020.

A19. Public Health England. COVID-19: guidance for health professionals. 2020. Online document at https://www.gov.uk/government/collections/wuhan-novel-coronavirus, accessed March 18, 2020.

A20. Health Protection Scotland (HPS). Novel coronavirus (COVID-19) guidance for primary care management of patients in primary care Including general dental practice, general medical practice, optometry and pharmacy Version 11.1. 2020. Online document at https://hpssubrepo.blob.core.windows.net/hps-website/nss/2930/documents/1_covid-19-guidance-for-primary-care.pdf, accessed April 22, 2020.

A21. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community. NICE guideline [NG165]. 2020. Online document at https://www.nice.org.uk/guidance/ng165, accessed April 22, 2020.

A22. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community. 2020. Online document at https://www.nice.org.uk/guidance/ng163, accessed April 22, 2020.

A23. Robert Koch Institute. Notes on detection, diagnostics and therapy of patients with COVID-19 [In German]. 2020. Online document at www.stakob.rki.de, accessed March 18, 2020.

(Appendix continues →)
A24. The Australian and New Zealand Intensive Care Society (ANZICS). COVID-19 Guidelines Version 1. 2020. Online document at https://www.anzics.com.au/wp-content/uploads/2020/03/ANZICS-COVID-19-Guidelines-Version-1.pdf, accessed April 22, 2020.

A25. Australia National COVID-19 Clinical Evidence Taskforce. Management of patients with moderate to severe COVID-19. 2020. Online document at https://covid19evidence.net.au/wp-content/uploads/2020/04/NATIONAL-COVID-19_TASKFORCE_FLOW-CHART_1_MODERATE-SEVERE_V1.0_3.4.2020.pdf, accessed April 22, 2020.

A26. Liu X, Zhang M, He L, Li Y. Chinese herbs combined with Western medicine for severe acute respiratory syndrome (SARS). Cochrane Database Syst Rev 2012;10:CD004882.

A27. Zhang DH, Wu KL, Zhang X, et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. J Integr Med 2020;18:152–158.

A28. Coronavirus disease 2019 (COVID-19). 2020. Online document at https://bestpractice.bmj.com/topics/en-gb/3000168, accessed March 18, 2020.

A29. McIntosh K, Hirsch MS, A B. Coronavirus disease 2019 (COVID-19). 2020. Online document at https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19, accessed March 18, 2020.

A30. DynaMed. COVID-19 (novel coronavirus). 2020. Online document at https://www.dynamed.com/condition/covid-19-novel-coronavirus#GUID-2AD27F14-FE83-474A-B25F-90AED2BA1EF5, accessed March 18, 2020.

A31. National University of Singapore, Saw Swee Hock School of Public Health. COVID-19 science report: Therapeutics. 2020. Online document at https://sph.nus.edu.sg/wp-content/uploads/2020/03/COVID-19-Science-Report-Therapeutics-13-Mar.pdf, accessed March 18, 2020.

A32. Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 2020;19:149–150.

A33. Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western Medicine for the management of 2019 novel Coronavirus disease. Am J Chin Med 2020;48:736–762.

A34. Cui HT, Li YT, Guo LY, et al. Traditional Chinese medicine for treatment of coronavirus disease 2019: A review. Tradit Med Res 2020;5:65–73.

A35. Lu H. Drug treatment options for the 2019–new coronavirus (2019-nCoV). Biosci Trends 2020;14:69–71.

A36. Luo H, Tang Q-I, Shang Y-x, et al. Can Chinese medicine be used for prevention of coronavirus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med 2020; 26(4):243–250.

A37. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020;92:479–490.

A38. Denis M. Overview of information available to support the development of medical countermeasures and interventions against COVID-19. 2020. Online document at https://rega.kuleuven.be/if/pdf_corona, accessed March 19, 2020.

A39. Gray PE, Belessis Y. The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good. Pharmacol Res 2020;156:104776.

A40. Han Ru WY, Dabrous M, Liang S, Qiu T, Toumi M. Chinese clinical studies for pharmacological treatments of coronavirus disease 2019 (COVID-19) (not peer-reviewed preprint). 2020. Online document at https://www.preprints.org/manuscript/202004.0279/v1, accessed March 18, 2020.

A41. Yang Y, Islam MS, Wang J, et al. Traditional Chinese medicine in the treatment of patients infected with 2019–new coronavirus (SARS-CoV-2): A review and perspective. Int J Biol Sci 2020;16:1708–1717.

A42. Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 2020;14:64–68.

A43. Ni L, Zhou L, Zhou M, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Front Med 2020;14:210–214.

A44. Xu K, Cai H, Shen Y, et al. [Management of corona virus disease-19 (COVID-19): The Zhejiang experience.] Zhejiang da xue xue bao. Yi xue ban 2020;49:0.

A45. Yang Q, Zhao T, Sun C, et al. New thinking in the treatment of 2019 novel coronavirus pneumonia. Complement Ther Clin Pract 2020;39:101131.

A46. Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment (letter to the editor). Pharmacol Res 2020;155:104743.

A47. WHO. Overview of the types/classes of candidate therapeutics. 2020. Online document at https://www.who.int/blueprint/priority-diseases/key-action/overview-ncov-therapeutics.pdf?ua=1, accessed March 19, 2020.